Lyseng-Williamson Katherine A
Wolters Kluwer Health, Adis, Auckland, New Zealand.
Drugs. 2008;68(18):2661-82. doi: 10.2165/0003495-200868180-00010.
Zoledronic acid 4 mg administered as a 15-minute infusion every 3-4 weeks is effective and well tolerated in the treatment of patients with breast cancer metastatic to bone. It is effective in reducing complications arising from metastatic bone disease in this patient population, with a clinical profile that compares favourably with that of pamidronate. Zoledronic acid administered on a less frequent schedule (every 3-6 months) has also shown potential in preventing cancer treatment-induced bone loss in pre- and postmenopausal women with breast cancer receiving adjuvant hormonal therapy. Preliminary data suggest that zoledronic acid may have antitumour effects, which may reduce the risk of overall disease progression in patients with malignant disease. Thus, zoledronic acid has a well established role as first-line treatment in patients with bone metastases secondary to breast cancer, and may prove useful as a preventive treatment for cancer treatment-induced bone loss or an adjuvant therapy in women with breast cancer.
每3 - 4周静脉输注15分钟给予4毫克唑来膦酸，在治疗骨转移乳腺癌患者中有效且耐受性良好。它能有效减少该患者群体中转移性骨病引起的并发症，其临床特征与帕米膦酸相比更具优势。按较低频率给药（每3 - 6个月一次）的唑来膦酸在预防接受辅助激素治疗的绝经前和绝经后乳腺癌女性癌症治疗引起的骨质流失方面也显示出潜力。初步数据表明唑来膦酸可能具有抗肿瘤作用，这可能降低恶性疾病患者总体疾病进展的风险。因此，唑来膦酸在继发于乳腺癌的骨转移患者中作为一线治疗具有明确的作用，并且可能被证明对癌症治疗引起的骨质流失的预防治疗或乳腺癌女性的辅助治疗有用。
